ANI Net Debt from 2010 to 2025

ANIP Stock

USD 64.26 0.09 0.14%

ANI Pharmaceuticals Net Debt yearly trend continues to be relatively stable with very little volatility. Net Debt is likely to grow to about 178.6 M this year. Net Debt is the total debt of ANI Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2000-03-31

Previous Quarter

480.4 M

Current Value

170.1 M

Quarterly Volatility

95.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of ANI Pharmaceuticals Correlation against competitors.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of ANI Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. ANI Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

ANI Net Debt Regression Statistics

	Arithmetic Mean	85,199,998
	Geometric Mean	70,202,890
	Coefficient Of Variation	118.30
	Mean Deviation	89,025,021
	Median	123,417,000
	Standard Deviation	100,790,731
	Sample Variance	10158.8T
	Range	296.6M
	R-Value	0.80
	Mean Square Error	3846.2T
	R-Squared	0.65
	Significance	0.0002
	Slope	17,023,794
	Total Sum of Squares	152381.6T

ANI Net Debt History

	2025	178.6 M
	2024	170.1 M
	2023	64.5 M
	2022	238.3 M
	2021	187.1 M
	2020	177.8 M
	2019	123.4 M

Other Fundumenentals of ANI Pharmaceuticals

Net Debt To E B I T D A

ANI Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Short Term Investments	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.96	0.7	0.0	0.97	0.99	0.96	-0.42	-0.22	0.17	0.69	0.98	0.18	0.97	0.94	0.62	0.75	-0.74	0.96	0.87	0.83	-0.74	0.85	0.75	0.82	-0.77
Total Stockholder Equity	0.96		0.69	0.07	0.93	0.91	0.97	-0.47	-0.17	0.17	0.68	0.95	0.21	0.89	0.86	0.69	0.57	-0.79	0.87	0.89	0.9	-0.76	0.81	0.8	0.85	-0.78
Net Debt	0.7	0.69		0.24	0.62	0.68	0.53	-0.47	-0.28	0.3	0.29	0.75	-0.38	0.62	0.55	0.59	0.34	-0.82	0.77	0.86	0.67	-0.78	0.47	0.37	0.55	-0.44
Retained Earnings	0.0	0.07	0.24		-0.15	-0.03	-0.05	-0.86	0.41	0.27	0.01	-0.04	-0.2	-0.05	-0.2	0.15	-0.18	-0.18	0.06	0.18	0.02	-0.06	-0.21	-0.24	-0.21	0.25
Accounts Payable	0.97	0.93	0.62	-0.15		0.96	0.96	-0.3	-0.36	0.25	0.64	0.98	0.27	0.94	0.96	0.57	0.74	-0.74	0.88	0.83	0.83	-0.73	0.88	0.83	0.87	-0.86
Total Liab	0.99	0.91	0.68	-0.03	0.96		0.93	-0.38	-0.24	0.17	0.68	0.97	0.17	0.99	0.96	0.56	0.83	-0.69	0.97	0.83	0.77	-0.71	0.84	0.7	0.77	-0.73
Total Current Assets	0.96	0.97	0.53	-0.05	0.96	0.93		-0.39	-0.19	0.14	0.74	0.94	0.37	0.92	0.91	0.61	0.67	-0.68	0.84	0.8	0.85	-0.7	0.85	0.83	0.85	-0.83
Common Stock	-0.42	-0.47	-0.47	-0.86	-0.3	-0.38	-0.39		-0.2	-0.32	-0.38	-0.4	-0.01	-0.37	-0.27	-0.43	-0.15	0.43	-0.42	-0.48	-0.42	0.36	-0.23	-0.21	-0.26	0.22
Short Term Debt	-0.22	-0.17	-0.28	0.41	-0.36	-0.24	-0.19	-0.2		-0.33	0.11	-0.33	0.1	-0.24	-0.33	-0.22	-0.18	0.33	-0.19	-0.28	-0.25	0.61	-0.34	-0.48	-0.4	0.34
Short Term Investments	0.17	0.17	0.3	0.27	0.25	0.17	0.14	-0.32	-0.33		-0.17	0.26	0.03	0.15	0.18	-0.02	0.06	-0.42	0.14	0.35	0.28	-0.27	0.24	0.23	0.28	-0.2
Current Deferred Revenue	0.69	0.68	0.29	0.01	0.64	0.68	0.74	-0.38	0.11	-0.17		0.65	0.31	0.7	0.66	0.39	0.56	-0.18	0.62	0.34	0.56	-0.37	0.59	0.6	0.55	-0.74
Net Receivables	0.98	0.95	0.75	-0.04	0.98	0.97	0.94	-0.4	-0.33	0.26	0.65		0.15	0.95	0.94	0.62	0.71	-0.79	0.93	0.89	0.85	-0.78	0.85	0.78	0.85	-0.82
Net Tangible Assets	0.18	0.21	-0.38	-0.2	0.27	0.17	0.37	-0.01	0.1	0.03	0.31	0.15		0.25	0.3	0.07	0.2	0.07	-0.02	-0.02	0.21	0.08	0.3	0.38	0.33	-0.35
Long Term Debt	0.97	0.89	0.62	-0.05	0.94	0.99	0.92	-0.37	-0.24	0.15	0.7	0.95	0.25		0.97	0.56	0.85	-0.62	0.95	0.78	0.75	-0.68	0.84	0.72	0.77	-0.72
Good Will	0.94	0.86	0.55	-0.2	0.96	0.96	0.91	-0.27	-0.33	0.18	0.66	0.94	0.3	0.97		0.47	0.85	-0.58	0.9	0.73	0.75	-0.62	0.89	0.77	0.84	-0.78
Long Term Debt Total	0.62	0.69	0.59	0.15	0.57	0.56	0.61	-0.43	-0.22	-0.02	0.39	0.62	0.07	0.56	0.47		0.3	-0.66	0.55	0.69	0.76	-0.74	0.58	0.63	0.6	-0.44
Long Term Investments	0.75	0.57	0.34	-0.18	0.74	0.83	0.67	-0.15	-0.18	0.06	0.56	0.71	0.2	0.85	0.85	0.3		-0.31	0.8	0.46	0.47	-0.35	0.78	0.51	0.53	-0.49
Treasury Stock	-0.74	-0.79	-0.82	-0.18	-0.74	-0.69	-0.68	0.43	0.33	-0.42	-0.18	-0.79	0.07	-0.62	-0.58	-0.66	-0.31		-0.69	-0.97	-0.76	0.81	-0.57	-0.53	-0.64	0.54
Intangible Assets	0.96	0.87	0.77	0.06	0.88	0.97	0.84	-0.42	-0.19	0.14	0.62	0.93	-0.02	0.95	0.9	0.55	0.8	-0.69		0.84	0.72	-0.69	0.76	0.59	0.69	-0.62
Property Plant Equipment	0.87	0.89	0.86	0.18	0.83	0.83	0.8	-0.48	-0.28	0.35	0.34	0.89	-0.02	0.78	0.73	0.69	0.46	-0.97	0.84		0.82	-0.83	0.67	0.6	0.72	-0.58
Capital Surpluse	0.83	0.9	0.67	0.02	0.83	0.77	0.85	-0.42	-0.25	0.28	0.56	0.85	0.21	0.75	0.75	0.76	0.47	-0.76	0.72	0.82		-0.75	0.87	0.86	0.93	-0.73
Short Long Term Debt	-0.74	-0.76	-0.78	-0.06	-0.73	-0.71	-0.7	0.36	0.61	-0.27	-0.37	-0.78	0.08	-0.68	-0.62	-0.74	-0.35	0.81	-0.69	-0.83	-0.75		-0.6	-0.69	-0.68	0.58
Net Invested Capital	0.85	0.81	0.47	-0.21	0.88	0.84	0.85	-0.23	-0.34	0.24	0.59	0.85	0.3	0.84	0.89	0.58	0.78	-0.57	0.76	0.67	0.87	-0.6		0.89	0.91	-0.74
Net Working Capital	0.75	0.8	0.37	-0.24	0.83	0.7	0.83	-0.21	-0.48	0.23	0.6	0.78	0.38	0.72	0.77	0.63	0.51	-0.53	0.59	0.6	0.86	-0.69	0.89		0.92	-0.81
Capital Stock	0.82	0.85	0.55	-0.21	0.87	0.77	0.85	-0.26	-0.4	0.28	0.55	0.85	0.33	0.77	0.84	0.6	0.53	-0.64	0.69	0.72	0.93	-0.68	0.91	0.92		-0.8
Accumulated Depreciation	-0.77	-0.78	-0.44	0.25	-0.86	-0.73	-0.83	0.22	0.34	-0.2	-0.74	-0.82	-0.35	-0.72	-0.78	-0.44	-0.49	0.54	-0.62	-0.58	-0.73	0.58	-0.74	-0.81	-0.8

Click cells to compare fundamentals

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	170.1 M	178.6 M
Net Debt To EBITDA	2.70	2.83

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Net Debt from 2010 to 2025

Latest ANI Pharmaceuticals' Net Debt Growth Pattern

ANI Net Debt Regression Statistics

ANI Net Debt History

Other Fundumenentals of ANI Pharmaceuticals

ANI Pharmaceuticals Net Debt component correlations

About ANI Pharmaceuticals Financial Statements

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY